Literature DB >> 15576891

Immunotherapy in the age of anti-IgE.

Ira Finegold1.   

Abstract

Recent results of allergen immunotherapy research have continued to validate efficacy and have also demonstrated a truly preventive aspect for this treatment. This review summarizes the basic principles of effective allergen immunotherapy and highlights some of the advances that have been published in the past year. These studies show that allergen immunotherapy, when done appropriately and properly, not only causes a decrease in symptoms and use of medication as well as an improved quality of life, but that the progression of disease from allergic rhinitis to asthma is substantially decreased and the development of new allergies is diminished. In addition, laboratory studies continue to demonstrate significant changes in the immune system with a shift in the immune pathway from TH2 toward a TH1 response. The impact of anti-IgE as a therapeutic agent with allergen immunotherapy is also be reviewed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15576891     DOI: 10.1385/CRIAI:27:2:075

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  34 in total

Review 1.  Immunotherapy for asthma: unfavorable studies.

Authors:  J M Portnoy
Journal:  Ann Allergy Asthma Immunol       Date:  2001-07       Impact factor: 6.347

Review 2.  Analyzing meta-analyses of specific immunotherapy in the treatment of asthma.

Authors:  I Finegold
Journal:  Ann Allergy Asthma Immunol       Date:  2001-07       Impact factor: 6.347

3.  Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium.

Authors:  D R Wilson; A M Irani; S M Walker; M R Jacobson; I S Mackay; L B Schwartz; S R Durham
Journal:  Clin Exp Allergy       Date:  2001-11       Impact factor: 5.018

4.  Long-term efficacy of preseasonal grass pollen immunotherapy in children.

Authors:  P A Eng; M Reinhold; H P E Gnehm
Journal:  Allergy       Date:  2002-04       Impact factor: 13.146

5.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

Authors:  Christian Möller; Sten Dreborg; Hosne A Ferdousi; Susanne Halken; Arne Høst; Lars Jacobsen; Antti Koivikko; Dieter Y Koller; Bodo Niggemann; Lene A Norberg; Radvan Urbanek; Erkka Valovirta; Ulrich Wahn
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

Review 6.  Systemic reactions and fatalities associated with allergen immunotherapy.

Authors:  R F Lockey; G L Nicoara-Kasti; D S Theodoropoulos; S C Bukantz
Journal:  Ann Allergy Asthma Immunol       Date:  2001-07       Impact factor: 6.347

7.  Preventive aspects of immunotherapy: prevention for children at risk of developing asthma.

Authors:  L Jacobsen
Journal:  Ann Allergy Asthma Immunol       Date:  2001-07       Impact factor: 6.347

Review 8.  The consideration of immunotherapy in the treatment of allergic asthma.

Authors:  P S Creticos
Journal:  Ann Allergy Asthma Immunol       Date:  2001-07       Impact factor: 6.347

Review 9.  Allergen-specific sublingual immunotherapy for respiratory allergy.

Authors:  G Passalacqua; G W Canonica
Journal:  BioDrugs       Date:  2001       Impact factor: 5.807

Review 10.  Sublingual immunotherapy for allergic rhinitis.

Authors:  D R Wilson; L I Torres; S R Durham
Journal:  Cochrane Database Syst Rev       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.